Japanese Alzheimer's Disease Neuroimaging Initiative
- Conditions
- Alzheimer's disease, mild cognitive impairment (MCI)
- Registration Number
- JPRN-UMIN000001374
- Lead Sponsor
- J-ADNI study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 600
Not provided
1. Parkinson' disease, multiple cerebral infarction, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, epilepsy, subdural hematoma, multiple sclerosis, head trauma with sequelae 2. Signs of brain infection, focal brain lesions (eg infarction) that may affect cognitive function. 3. Presence of pacemaker, arterial clip, artificial valves, artificial cochlea, and other magnetic/electroconductive metals in the body that may affect MRI 4. Major depression or bipolar disorder within past 1 year, addiction to alcohol or other drugs within past 2 years, presence of fatal or unstable diseases, vitamin B12 or folate deficiency, syphilis, thyroid function abnormality 5. administration of psychoactive drugs (defined in procedure manual) 6. administration of warfarin
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical/neuropsychological examinations: CDR, MMSEm WMS-R logical memory I & II, ADAS-Cog, clock drawing/copying, symbol, block design, digit span, knowledge, fluency, trail making test A & B, Boston naming test, geriatric depression scale, Neuropsychiatric Inventory Q, FUnctional activity questionnaire Magnetic Resonance Imaging of brain: 1.5 tesla MRI in all cases, 3 tesla in 25% of cases Positron Emission Tomogram: fluorodeoxy glucose PET in 50% of cases Lumbar puncture: in 50% cases at baseline and 12 months blood and urine collection in all cases amyloid PET imaging (25% cases)
- Secondary Outcome Measures
Name Time Method